Chinese investors are pumping money into US drug start-ups as Beijing seeks to become a global leader in new medicines, adding to a flood of cash flowing to groundbreaking health firms.
Chinese investors are pumping money into US drug start-ups as Beijing seeks to become a global leader in new medicines, adding to a flood of cash flowing to groundbreaking health firms.